Kathryn Nielsen, NP
Primary Care · Idaho Falls, IDNPI 1619416674
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,108 of the $5,288 with a category attached, or 77.7%. 39 manufacturers reported payments, led by Medtronic at 28.3% of the total. Reporting peaked in 2024 at $2,169 and has fallen 62.3% since, to $818 in 2025. Among primary care clinicians in ID with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 235 payments — averaging $22.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$1K
- Novartis$500
- Lilly USA, LLC$402
- Abbott$330
- Novo Nordisk$254
- AbbVie$247
- plus $2K from 33 others
What the payments were for
- Travel & lodging$1,16022%
- Food & beverage$4,10878%
- Education$200%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 14 | $1,497 |
| Novartis | 56 | $500 |
| Lilly USA, LLC | 26 | $402 |
| Abbott | 20 | $330 |
| Novo Nordisk | 12 | $254 |
| AbbVie | 7 | $247 |
| Bayer | 12 | $187 |
| Amgen(2 entities) | 6 | $174 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $170 |
| Radius Health, Inc. | 8 | $161 |
| Esperion Therapeutics, Inc. | 3 | $141 |
| Boehringer Ingelheim | 4 | $100 |
| Idorsia Pharmaceuticals US Inc | 3 | $99 |
| Xeris Pharmaceuticals, Inc. | 5 | $93 |
| Insulet Corporation | 2 | $89 |
| Recordati_rare_diseases_inc. | 6 | $79 |
| AstraZeneca | 6 | $76 |
| Ascendis Pharma Endocrinology Inc | 5 | $73 |
| Inspire Medical Systems, Inc. | 2 | $60 |
| Kyowa Kirin, Inc. | 3 | $57 |
| Corcept Therapeutics | 3 | $55 |
| Madrigal Pharmaceuticals | 3 | $50 |
| Johnson & Johnson | 3 | $44 |
| Tolmar, Inc. | 2 | $39 |
| Ultragenyx Pharmaceutical Inc. | 3 | $39 |
| Dexcom, Inc. | 1 | $38 |
| Sanofi-aventis U.S. LLC | 2 | $34 |
| IBSA Pharma Inc. | 2 | $23 |
| Alnylam Pharmaceuticals Inc. | 1 | $20 |
| Tandem Diabetes Care, Inc. | 1 | $20 |
| Amryt Pharma Holdings Ltd | 1 | $19 |
| Eton Pharmaceuticals, Inc. | 1 | $19 |
| Pfizer | 1 | $18 |
| Biomarin Pharmaceutical Inc. | 1 | $16 |
| EUSA Pharma (US) LLC | 1 | $15 |
| Boston Scientific | 1 | $14 |
| Nevro Corp. | 1 | $13 |
| Amarin Pharma, Inc. | 1 | $13 |
| Phathom Pharmaceuticals, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$1,139
- CAPLYTA$130
- UBRELVY$127
- NEXLETOL$125
- NEXLIZET$125
How this compares
$5,289 in reported general payments places this provider in the 95th percentile of 48 primary care providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 352 | $373,274 |
| OzempicSemaglutide | 173 | $195,423 |
| TrulicityDulaglutide | 76 | $79,021 |
| JardianceEmpagliflozin | 62 | $52,638 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 14 | $16,566 |
| Bydureon BciseExenatide Microspheres | 13 | $10,303 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 73 | $8,669 |
| Humalog Kwikpen U-100Insulin Lispro | 15 | $3,984 |
| Levothyroxine Sodium | 335 | $3,735 |
| Novolog FlexpenInsulin Aspart | 13 | $2,697 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 18 | $2,600 |
| Rosuvastatin Calcium | 225 | $2,071 |
| SynthroidLevothyroxine Sodium | 23 | $1,540 |
| Gabapentin | 47 | $1,222 |
| Metformin Hcl ErMetformin Hcl | 120 | $733 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $402 | $452,296428 claims |
| Novo NordiskOzempic | $254 | $195,423173 claims |
| Boehringer IngelheimJardiance | $100 | $52,63862 claims |
| AbbVieSynthroid | $247 | $1,54023 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 48 primary care providers in Idaho.
Other primary care in Idaho Falls
- Bradley RadfordIdaho Falls$8K
- Justin RogersIdaho Falls$3K
- Bryce AndersenIdaho Falls$1K
- Elizabeth CameronIdaho Falls$38
- Jessica ButterfieldBoise$5K
- Teirza BristowKellogg$4K
- Lynnette KhandakerBoise$4K
- Billie Sue MayoNampa$2K
- Marquee RicksRexburg$2K
- Helene EdmoLava Hot Springs$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.